GLP-1 before and after photos: what they can and cannot tell you

The visual story is real. It is also incomplete.

TL;DR

• A photo shows scale weight loss, not body composition or health markers.
• Muscle loss does not show up on the surface until it is substantial.
• Published trials report average weight reductions of 12 to 21 percent with semaglutide or tirzepatide over 68 to 72 weeks.

What it is

A before-and-after photo is one of the oldest forms of weight-loss marketing. With GLP-1 medicines (in plain English: a class of medications that mimic the body’s fullness signal), these photos now flood social feeds. They tell part of the story — a real story, in many cases — but they also leave out the parts that matter most over time. This post is a quick guide to reading them honestly.

How it works

GLP-1 medicines like semaglutide and tirzepatide work like an extra-loud fullness signal sent from the gut to the brain. Think of it like the dashboard light on a car that says the tank is full — only here, the light comes on sooner and stays on longer. People eat less, often feel less interested in food, and lose weight. A photo can capture the result. It cannot capture what is happening underneath — bone, muscle, fat ratio, or lab markers like fasting glucose.

Who asks about it

People come to this topic when they are weighing whether to start a GLP-1 program. They want to know what realistic results look like. Many have already scrolled through dozens of social-media transformations and are trying to separate signal from noise.

What the research says

The STEP trials of semaglutide reported average weight reductions around 15 percent over 68 weeks (NEJM, 2021). The SURMOUNT trials of tirzepatide reported average weight reductions around 21 percent over 72 weeks. About 4 in 10 people experience nausea, usually in the first weeks. Studies also report a meaningful share of weight lost is lean mass — often 20 to 40 percent of the total, depending on protein intake and resistance training. Photos rarely show this.

What to know before considering it

GLP-1 medicines require a licensed clinician evaluation, a baseline lab panel, and ongoing monitoring. Compounded GLP-1 is prepared by state-licensed 503A pharmacies from FDA-approved active pharmaceutical ingredients and is not itself FDA-approved. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, February 2026). No price comparison to branded product belongs in patient education.

The Halftime POV

We do not publish before-and-after photos. Aspirational images do not replace baseline labs, body composition tracking, or a real conversation with a clinician. The number on the scale is only one of about a dozen markers that should move on a properly run GLP-1 program.

Related reading:

• GLP-1 and muscle loss: the science of sarcopenia risk
• Labs to monitor during GLP-1 therapy
• GLP-1 weight rebound: what the research shows

FAQ

Q: Are GLP-1 before and after photos accurate? A: They show one person’s surface change, not average response or body composition.

Q: Do photos show muscle loss? A: Often no. Muscle loss is invisible on the surface until it is substantial.

Q: How much weight is typical on GLP-1 therapy? A: Trials report average reductions of 12 to 21 percent over 68 to 72 weeks. Individual results vary.

Disclaimer

This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. Join the waitlist for updates.

Sources

• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. https://pubmed.ncbi.nlm.nih.gov/
• US Food and Drug Administration. GLP-1 compounding policy updates. https://www.fda.gov/news-events/press-announcements